Patent ID: 7691872
Filing Date: 2010-04-06
Classification: A61K,A61P

Abstract:
1. A method for increasing the free drug levels of a camptothecin drug that binds human serum albumin (HSA) during anti-topoisomerase I-based therapy in humans, said method comprising administering, to a human or animal patient in need of said therapy, at least one HSA-binding compound, wherein said HSA-binding compound is a phospholipid, so as to block the camptothecin binding site on HSA and thus reduce the binding of the camptothecin drug to HSA in human blood or plasma so that the free drug levels of the camptothecin drug will be increased and so that greater levels of the camptothecin will reach the drug target at the treatment site, wherein the HSA-binding compound is administered separately from the camptothecin drug.